What’s Propelling Celyad SA (CYAD) to Decrease? The Stock Formed a Wedge Down Chart Pattern

June 16, 2018 - By Maria Brooks

Celyad SA (NASDAQ:CYAD) Logo

The stock of Celyad SA (CYAD) formed a down wedge with $25.02 target or 9.00 % below today’s $27.49 share price. The 9 months wedge indicates high risk for the $381.72M company. If the $25.02 price target is reached, the company will be worth $34.35 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock decreased 2.62% or $0.74 during the last trading session, reaching $27.49. About 12,894 shares traded or 7.84% up from the average. Celyad SA (NASDAQ:CYAD) has declined 15.49% since June 16, 2017 and is downtrending. It has underperformed by 28.06% the S&P500.

Celyad SA (NASDAQ:CYAD) Ratings Coverage

Among 3 analysts covering Celyad (NASDAQ:CYAD), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Celyad had 3 analyst reports since April 27, 2018 according to SRatingsIntel. Piper Jaffray maintained Celyad SA (NASDAQ:CYAD) rating on Friday, April 27. Piper Jaffray has “Buy” rating and $7400 target. The stock of Celyad SA (NASDAQ:CYAD) earned “Buy” rating by SunTrust on Thursday, May 31.

More notable recent Celyad SA (NASDAQ:CYAD) news were published by: Equitiesfocus.com which released: “Jazz Pharmaceuticals (JAZZ) & CELYAD SA/ADR (NASDAQ:CYAD) Critical Review” on June 13, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on May 31, 2018, Benzinga.com published: “23 Stocks Moving In Monday’s Pre-Market Session” on May 21, 2018. More interesting news about Celyad SA (NASDAQ:CYAD) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For May 31, 2018” published on May 31, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” with publication date: May 18, 2018.

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell therapies. The company has market cap of $381.72 million. The firm utilizes its expertise in cell engineering to target cancer. It currently has negative earnings. The Company’s CAR-T cell platform has the potential to treats a range of solid and hematologic tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: